Develops high-affinity anti-idiotypic antibodies for the precise detection of CAR T-cells, enabling accurate monitoring and quality control in CAR T-cell therapies. These antibodies, compatible with flow cytometry and PCR, offer market-leading sensitivity of 1 in 100,000 and specificity for CAR signaling, addressing the critical need for reliable detection in clinical and research settings.
Funding
Funding not disclosed
Founders
Product
Problem
Monitoring CAR T-cell therapies requires highly sensitive and specific detection methods to ensure accurate assessment of treatment efficacy and potential risks. Current detection methods may lack the necessary sensitivity to detect low levels of CAR T-cells or may exhibit cross-reactivity, leading to inaccurate results.
Solution
Cytoart develops high-affinity anti-idiotypic antibodies that enable precise and sensitive detection of CAR T-cells in patient samples. These antibodies specifically target the unique variable regions of CARs, ensuring minimal cross-reactivity and accurate quantification of CAR T-cell populations. Compatible with flow cytometry and PCR-based assays, Cytoart's antibodies offer market-leading sensitivity, capable of detecting CAR T-cells at levels as low as 1 in 100,000 cells. This enhanced sensitivity allows for improved monitoring of CAR T-cell persistence, proliferation, and potential for relapse, providing clinicians and researchers with valuable insights into treatment dynamics. Cytoart's anti-idiotype antibodies support all FDA-approved CAR-T therapies, providing a reliable tool for assessing treatment response and optimizing patient outcomes.
Target Audience
The primary customers are clinicians, researchers, and pharmaceutical companies involved in CAR T-cell therapy development, monitoring, and clinical research.
Features
- High-affinity anti-idiotypic antibodies with specificity for CAR T-cell variable regions (scFv)
- Market-leading sensitivity, detecting CAR T-cells at levels as low as 1 in 100,000
- Compatibility with flow cytometry and PCR-based assays for versatile detection methods
- Designed for Ligand Binding, Pharmacokinetics (PK), Anti-Drug Antibody (ADA)/Neutralizing Antibody (Nab) Analysis assays
- Engineered for long-term in-vivo CAR monitoring
- Supports all FDA-approved CAR-T therapies
- Available in multiple formats, including PE and Alexa Fluor 647 conjugates
- Rigorous quality control to ensure minimal batch-to-batch variation